enalapril (vasotec) Report issue

Small molecule Approved FDA Priority Review FDA
AACT ChEMBL DrugBank Drug Central Drugs@FDA KEGG MeSH PubChem repoDB

Active Ingredient History

NOW
  • Now
Enalapril (marketed as Vasotec in the US, Enaladex and Renitec in some other countries) is an angiotensin-converting-enzyme (ACE) inhibitor used in the treatment of hypertension, diabetic nephropathy, and some types of chronic heart failure. Enalapril, after hydrolysis to enalaprilat, inhibits angiotensin-converting enzyme (ACE) in human subjects and animals. ACE is a peptidyl dipeptidase that catalyzes the conversion of angiotensin I to the vasoconstrictor substance, angiotensin II. Angiotensin II also stimulates aldosterone secretion by the adrenal cortex. The beneficial effects of enalapril in hypertension and heart failure appear to result primarily from suppression of the renin-angiotensin-aldosterone system. Inhibition of ACE results in decreased plasma angiotensin II, which leads to decreased vasopressor activity and to decrease aldosterone secretion.   NCATS

Chemistry

More Chemistry

Pharmacology

  • Mechanism of Action:
  • Multi-specific: Missing data
  • Black Box: Yes
  • Availability: Prescription Only
  • Delivery Methods: Parenteral
  • Pro Drug: No

Drug Pricing (per unit)

United States

$0.0000 - $24.7697

Australia

$0.0556 - $0.2667
More Pricing Detail

Note: This drug pricing data is preliminary, incomplete, and may contain errors.

Alternative names

1-(n-((s)-1-carboxy-3-phenylpropyl)-l-alanyl)-l-proline 1'-ethyl ester | analapril | ednyt | enalapril | enalaprila | enalapril acid | enalaprilat | enalaprilat anhydrous | enalaprilat dihydrate | enalaprilate | enalaprilat hydrate | enalaprilic acid | enalapril maleate | enalaprilum | enapren | enarenal | innovace | lexxel | mk-421 | mk-422 | pralenal 10 | pralenal 20 | pralenal 2.5 | pralenal 5 | renitec | (s)-1-(n-(1-(ethoxycarbonyl)-3-phenylpropyl)-l-alanyl)-l-proline | (s)-1-{(s)-2-[1-((s)-ethoxycarbonyl)-3-phenyl-propylamino]-propionyl}-pyrrolidine-2-carboxylic acid | vaseretic | vasotec | xanef

Organizations (183)

Research & Development (149)

Organization Org Type FDA approvals Clinical Trials involvement Org ID Force Sort

Marketing (37)

Organization Org Type FDA approvals Clinical Trials involvement Org ID Force Sort

Indications (75)

Approved Indications (3)


 

Heart Failure (approved 1985)

Hypertension

Ventricular Dysfunction, Left (approved 1985)

Experimental Indications - Clinical Trial Phases 1-4 (75)


 

Angioplasty (Phase 2/Phase 3)

Arterial Occlusive Diseases (Phase 2)

Arthritis, Rheumatoid (Phase 2)

Atherosclerosis (Phase 4)

Barrett Esophagus (Early Phase 1)

Blood Pressure (Phase 2)

Breast Neoplasms (Phase 3)

Carboxylesterase (Phase 4)

Cardiomyopathies (Phase 3)

Cardiomyopathy, Dilated (Phase 4)

Cardiotoxicity (Phase 4)

Cardiovascular Diseases (Phase 4)

Cerebral Hemorrhage (Phase 2)

Chagas Cardiomyopathy (Phase 4)

Chagas Disease (Phase 4)

Cicatrix, Hypertrophic (Phase 2/Phase 3)

Complement Pathway, Classical (Phase 2)

Contrast Media (Phase 2/Phase 3)

Coronary Disease (Phase 3)

COVID-19 (Phase 3)

Diabetes Mellitus (Phase 4)

Diabetes Mellitus, Type 1 (Phase 2)

Diabetes Mellitus, Type 2 (Phase 4)

Drug-Related Side Effects and Adverse Reactions (Phase 4)

Endomyocardial Fibrosis (Phase 3)

Erectile Dysfunction (Phase 3)

Essential Hypertension (Phase 4)

Esterases (Phase 4)

Glomerulonephritis (Phase 2)

Glomerulonephritis, IGA (Phase 4)

Glomerulonephritis, Membranoproliferative (Phase 2)

Healthy Volunteers (Phase 4)

Heart Defects, Congenital (Phase 3)

Heart Diseases (Phase 4)

Heart Failure (Phase 4)

Heart Failure, Diastolic (Phase 3)

Heart Failure, Systolic (Phase 4)

Heart Septal Defects, Ventricular (Phase 3)

Hematopoietic Stem Cell Transplantation (Phase 3)

Homocysteine (Phase 2/Phase 3)

Hyperhomocysteinemia (Phase 4)

Hypertension ()

Hypotension (Phase 4)

Kidney Diseases (Phase 4)

Kidney Failure, Chronic (Phase 4)

Leukemia, Myeloid, Acute (Phase 3)

Lung Neoplasms (Phase 2)

Lymphoma (Phase 3)

Lymphoma, Non-Hodgkin (Phase 3)

Melanoma (Phase 2)

Membranes (Phase 4)

Metabolic Syndrome (Phase 4)

Multiple Myeloma (Phase 3)

Muscular Dystrophies (Phase 3)

Myocardial Ischemia (Phase 3)

Neoplasms (Phase 3)

Oxidative Stress (Phase 2)

Peritoneal Dialysis, Continuous Ambulatory (Phase 4)

Pharmacokinetics (Phase 1)

Plasma (Phase 2)

Precursor Cell Lymphoblastic Leukemia-Lymphoma (Phase 3)

Pre-Eclampsia (Phase 2)

Proteinuria (Phase 3)

Pseudohypoaldosteronism (Phase 2)

Radiation Pneumonitis (Phase 2)

Renal Dialysis (Phase 4)

Renal Insufficiency, Chronic (Phase 4)

Severe acute respiratory syndrome-related coronavirus (Phase 4)

ST Elevation Myocardial Infarction (Phase 3)

Stroke (Phase 4)

Thrombosis (Phase 2)

Vaccines (Phase 4)

Vascular Diseases (Phase 2)

Ventricular Dysfunction, Left (Phase 4)

Virus Diseases (Phase 4)

Overview

  • Highest Phase: Phase 4
  • # of Trials: 122
  • # of Trial Organizations: 149

Trials by Phase

Trial Phase Start Date Organizations Indications

Feedback

Data collection and curation is an ongoing process for CDEK - if you notice any information here to be missing or incorrect, please let us know! When possible, please include a source URL (we verify all data prior to inclusion).

Report issue